Combo pill approved for adults with type 2 diabetes

November 3, 2014

FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.

FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.

It is approved as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both dapagliflozin and metformin is appropriate.

Doctors say type 2 diabetes needs more holistic approach

Xigduo XR is the first once-daily tablet combining a sodium glucose co-transporter 2 (SGLT2) inhibitor and metformin HCI extended-release, a biguanide, approved in the United States.

 

“The addition of Xigduo XR to our U.S. diabetes portfolio is further evidence of AstraZeneca’s commitment to develop new treatment options for patients with type 2 diabetes,” said Elisabeth Björk, head of cardiovascular & metabolism, global medicines development, AstraZeneca. “The approval of once-daily Xigduo XR provides prescribers and adult patients with another treatment choice, supporting a more [personalized] approach to disease management.”

Xigduo XR removes glucose from the body through the kidneys.  Click here to read Xigduo XR dosing instructions.